Mirum Pharmaceuticals
Public biopharma developing therapies for rare liver diseases; maker of FDA-approved LIVMARLI for Alagille syndrome. Founded 2018, HQ Foster City. ~392 staff. Public (NASDAQ: MIRM) since 2019.
What is Mirum Pharmaceuticals?
Mirum Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing therapies for rare, debilitating liver diseases that often have few or no effective treatment options. Its lead approved product is LIVMARLI (maralixibat), which the FDA approved in September 2021 for cholestatic pruritus (severe itching caused by bile buildup) in patients with Alagille syndrome, a rare genetic liver disorder. Mirum's broader pipeline, including a related compound, volixibat, targets other rare cholestatic liver conditions such as progressive familial intrahepatic cholestasis (PFIC). The company's programs trace back to licensing maralixibat and volixibat from Shire (now part of Takeda). Mirum was founded in 2018 and is headquartered in Foster City, California. Chris Peetz, Co-Founder, President, and CEO, led the company through a rapid clinical development strategy that culminated in its IPO on the Nasdaq (ticker MIRM) on July 18, 2019, and through LIVMARLI's subsequent FDA approval. Mirum employs roughly 392 people worldwide.
Mission & values
Develop and deliver transformative therapies for rare, debilitating liver diseases where patients have had few or no treatment options.
Qualifications
Mirum hires across the functions of a commercial-stage public biotech. On the science side: clinical development and clinical operations (running trials for its pipeline in rare liver diseases), medical affairs, regulatory affairs, biostatistics, and pharmacovigilance/drug safety. On the commercial side, since LIVMARLI is an approved, marketed product: sales and market access, commercial operations, patient services and support (important for rare-disease patients as they work through access and coverage), and marketing. It also hires software/IT, finance, legal, and people functions. Application flow lives at mirumpharma.com/about-us/careers. As a public company headquartered in Foster City, California, corporate, commercial, and some clinical roles may be remote or hybrid, while certain lab, clinical-operations, or manufacturing-adjacent roles are more likely on-site; roles generally require the relevant country's work authorization. Rare-disease, hepatology, or biotech commercial experience is a strong signal. Check each posting for location and remote eligibility.
Leadership
Chris Peetz
Co-Founder, President & Chief Executive Officer
Co-founded Mirum Pharmaceuticals in 2018 and leads it as President and CEO, guiding the company through its 2019 Nasdaq IPO and the FDA approval of LIVMARLI for Alagille syndrome in 2021.
Hiring process
-
1
Apply at mirumpharma.com careers
Browse clinical development, medical affairs, regulatory, commercial/sales, market access, patient services, and corporate roles and submit through the Mirum careers site.
-
2
Recruiter screen
Confirms role fit, level, country and work authorization, remote/hybrid vs on-site expectations, and pay.
About 7 days
-
3
Technical or role-specific interview
Clinical/scientific: trial design, regulatory, or therapeutic-area depth. Commercial: a market-access or sales scenario relevant to rare disease.
About 10 days
-
4
Panel interviews
Cross-functional interviews with the team and stakeholders on depth and fit for a mission-driven rare-disease biotech.
About 10 days
-
5
Offer
Offer with base, bonus, and equity (RSUs/options) as a public company, aligned to role and location.
About 7 days
Funding
Awards & recognition
-
FDA approval of LIVMARLI for Alagille syndrome cholestatic pruritus · 2021
FDA / Mirum Pharmaceuticals
-
IPO on the Nasdaq under ticker MIRM · 2019
Mirum Pharmaceuticals
Company information
- Industry: Biotech / Rare Liver Disease Therapeutics
- Location: Foster City, CA, USA (public company; some remote/hybrid)
- Founded: 2018
- Employees: 392
- Website: mirumpharma.com ↗
- LinkedIn: Company page ↗